Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Purpose

AC220, a FLT-3 inhibitor, is being investigated for the treatment of Acute Myeloid Leukemia (AML). The objective of this study was to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AC220 and its active metabolite AC886 following once daily escalating oral dosing to patients with relapsed or treatment-refractory AML.

Download Poster

Effect of Food on the Pharmacokinetics of Ulifloxacin, a Fluoroquinolone for Bacterial Gastroenteritis Treatment, in Healthy Subjects After Oral Dosing of the Prodrug Prulifloxacin

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period

Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Subscribe to Our Newsletter